u/nadia_fonseca

the mechanism is different, the side effect profile reflects it

Small correction: the trial was 16 weeks, not 26. Does not change your point but people will quote it.

the co-agonism question is real and interesting

axis labels included, always

Asked QSC for the batch-specific COA and they sent it within six hours, full document, batch number, date, everything. That is the baseline.

Disagree but this is the good kind of wrong — it is specific enough to be checked.

the counterion is part of the mass you paid for

No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.

Strongly agree. REDEFINE is phase 8, not final.

Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.

REDEFINE which arm?

Not convinced. The evidence does not support that reading.

the amylin agonist pool is small, community is satiety

Every time this gets posted it hits the front page and every time someone has to re-explain it.

The confident tone is doing a lot of work that the evidence is not.

Slight fix: the number was 99.1, not 93.7. Decimal point, but a fairly consequential one.

The satiety on amylin analogs is described as physically different. GLP-1 reduces appetite noise, amylin does satiety.

long-acting amylin is co-agonism, different satiety profile

more of this energy please

Adding to this: half-life is doing more work than the comment implies.

Strongly agree. Mass% and area% are answering different questions on the same document.